Sympathetic activation and endothelial dysfunction in polycystic ovary syndrome are not explained by either obesity or insulin resistance-Reference-Cited by-同舟云学术

Sympathetic activation and endothelial dysfunction in polycystic ovary syndrome are not explained by either obesity or insulin resistance

Published:2015-05-13 Issue:6 Volume:83 Page:812-819
ISSN:0300-0664
Container-title:Clinical Endocrinology
language:en
Short-container-title:Clin Endocrinol

Author:

Lambert Elisabeth A.¹²,Teede Helena³,Sari Carolina Ika¹,Jona Eveline³,Shorakae Soulmaz³,Woodington Kiri¹,Hemmes Robyn¹,Eikelis Nina¹,Straznicky Nora E.¹,De Courten Barbora³,Dixon John B.⁴,Schlaich Markus P.⁵⁶,Lambert Gavin W.¹⁷

Affiliation:

1. Human Neurotransmitters Laboratory; Baker IDI Heart & Diabetes Institute; Melbourne Vic. Australia

2. Department of Physiology; Monash University; Clayton Vic. Australia

3. Monash Centre for Health Research and Implementation; Monash University and Monash Health; Clayton Vic. Australia

4. Clinical Obesity Research laboratory; Baker IDI Heart & Diabetes Institute; Melbourne Vic. Australia

5. Hypertension & Kidney Disease Laboratories; Baker IDI Heart & Diabetes Institute; Melbourne Vic. Australia

6. Primary Health Care and the Department of Cardiovascular Medicine; Alfred Hospital; Prahran Vic. Australia

7. Faculty of Medicine, Nursing and Health Sciences; Monash University; Clayton Vic. Australia

Funder

National Health and Medical Research Council

Allergan, Inc

Medtronic, Abbott and Servier, Australia

Publisher

Wiley

Subject

Endocrinology, Diabetes and Metabolism,Endocrinology

Reference36 articles.

1. Prevalence of polycystic ovary syndrome in a sample of Indigenous women in Darwin, Australia;Boyle;Medical Journal of Australia,2012

2. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis;Lim;Human Reproduction Update,2012

3. Anxiety and depression in polycystic ovary syndrome: a systematic review and meta-analysis;Barry;Human Reproduction,2011

4. Gestational diabetes and type 2 diabetes in reproductive-aged women with polycystic ovary syndrome;Joham;Journal of Clinical Endocrinology and Metabolism,2014

5. Black women with polycystic ovary syndrome (PCOS) have increased risk for metabolic syndrome and cardiovascular disease compared with white women with PCOS [corrected];Hillman;Fertility and Sterility,2014

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring heart rate variability in polycystic ovary syndrome: implications for cardiovascular health: a systematic review and meta-analysis;Systematic Reviews;2024-07-24

2. Targeting the sympathetic nervous system with the selective imidazoline receptor agonist moxonidine for the management of hypertension: an international position statement;Journal of Hypertension;2024-05-15

3. Increased Vasoactive Intestinal Peptide (VIP) in polycystic ovary syndrome patients undergoing IVF;Frontiers in Endocrinology;2024-05-07

4. Polycystic ovary syndrome;Nature Reviews Disease Primers;2024-04-18

5. Reducing the Risk of Pre-Eclampsia in Women with Polycystic Ovary Syndrome Using a Combination of Pregnancy Screening, Lifestyle, and Medical Management Strategies;Journal of Clinical Medicine;2024-03-20